- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
risankizumab is an approved drug (Japan, FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) . It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|